Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Fineline Cube Apr 21, 2026
Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Fineline Cube Apr 21, 2026
Company Drug

iRegene’s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy

Fineline Cube Dec 1, 2025

iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving...

Company Deals

Proviva’s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost

Fineline Cube Dec 1, 2025

Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led...

Company Drug

Pfizer-Astellas’ PADCEV Wins FDA Approval for Perioperative Bladder Cancer

Fineline Cube Nov 29, 2025

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food...

Company Drug

GenSci’s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials

Fineline Cube Nov 29, 2025

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci...

Company Drug

Jiuzhou Pharmaceutical Wins Tentative FDA Approval for Generic Janumet XR

Fineline Cube Nov 28, 2025

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (SHA: 603456) announced that its Abbreviated New Drug Application (ANDA)...

Company Drug

Hengrui’s Ivarmacitinib Wins NMPA Nod for Vitiligo Clinical Trials

Fineline Cube Nov 28, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that Ivarmacitinib Tablets and SHR0302...

Company Drug

Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise

Fineline Cube Nov 28, 2025

Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China’s first self‑developed CD19‑targeting CAR‑T...

Company Drug

Innovent’s Picankibart Wins NMPA Approval for Psoriasis as IL-23p19 Inhibitor

Fineline Cube Nov 28, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that Picankibart Monoclonal Antibody Injection (IBI112), branded XINMEIYUE, received...

Company Deals

Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation

Fineline Cube Nov 28, 2025

Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB...

Company Drug

Boan Biotech’s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases

Fineline Cube Nov 27, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self‑developed Aflibercept Intravitreal Injection (Boyoujing)...

Company Deals

Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront

Fineline Cube Nov 27, 2025

Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc....

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg sNDA Submitted for Weight Management

Fineline Cube Nov 27, 2025

Novo Nordisk A/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA)...

Company Drug

CSPC’s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management

Fineline Cube Nov 27, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed recombinant fully human anti‑ActRIIA/IIB monoclonal...

Company Medical Device

MicroTech’s LinX CGM Wins India Approval, Expanding Asia Diabetes Monitoring

Fineline Cube Nov 27, 2025

MicroTech Medical (Hangzhou) Co., Ltd. (HKG: 2235) announced that its LinX Continuous Glucose Monitoring (CGM)...

Medical Device

Bio-heart’s IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System

Fineline Cube Nov 27, 2025

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that its Iberis Multi-Electrode Renal Denervation...

Company Drug

IASO-Bio’s Fucaso Wins Hong-Kong Approval as First China CAR-T

Fineline Cube Nov 27, 2025

IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA‑targeted CAR‑T cell...

Company Drug

BeOne’s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma

Fineline Cube Nov 27, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. FDA has accepted its...

Company Deals

Patronus Biotech Gates Foundation Grant Accelerates Malaria Vaccine Development

Fineline Cube Nov 27, 2025

Patronus Biotech Pte. Ltd. announced it has received a grant from the Gates Foundation to...

Company Deals

Innova Therapeutics Acquires Enci Therapeutics’ IVT-8086 Cancer Program

Fineline Cube Nov 27, 2025

Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT‑8086,...

Company Drug

Gene Key’s iNKT Cell Therapy Wins NMPA Nod for ARDS, First Allogeneic Ready-to-Use

Fineline Cube Nov 27, 2025

Beijing Gene Key Life Technology Co., Ltd. announced that its GKL‑006RTU Injection, China’s first novel...

Posts pagination

1 … 62 63 64 … 654

Recent updates

  • China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive
  • FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
  • Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases
  • Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026
  • Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Company Digital

Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases

Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.